Explore more Johnson & Johnson sites:
Learn More About Janssen's Phase 3 COVID-19 Vaccine Candidate Clinical Trials
By clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
Learn More
By clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
Share
Global Disease Challenges
hile the world continues to face ongoing challenges with HIV and tuberculosis, and many unknown and emerging threats, there is also an increasing shift in burden of disease toward noncommunicable diseases (NCDs) and mental health. At Johnson & Johnson, we are passionate about our work to save and improve people’s lives. We forge partnerships and identify new ways to pioneer human ingenuity to accelerate the development of new drug regimens, support the strengthening of healthcare systems and break down barriers to access in resource-limited settings.
Our Aspiration: A world where innovations and holistic health solutions prevent, control and eliminate global disease challenges and epidemics.
5-Year Target: 175 million individuals will have benefited from Johnson & Johnson solutions that prevent, control and eliminate global diseases.
Status: Exceeded
Our Impact:
• How Johnson & Johnson Is Helping Tackle a Devastating Tropical Disease That Impacts Kids
• Working to Make HIV History
Related Content
Johnson & Johnson has signed up to the 2030 UN Sustainable Development Goals—the world’s road map for progress.
More From Johnson & Johnson
Johnson & Johnson just announced the launch of a Phase 3 clinical trial for its COVID-19 vaccine candidate. But what does this step in the process really mean? We asked two experts whose job it is to test vaccines to help demystify the clinical trial process—step by step.
The heart condition affects up to six million Americans, and raises the risk of stroke five-fold. One patient describes what it was like to learn she had atrial fibrillation—and the unexpected positive impact it has had on her life.
Njira Lugogo, M.D., is a pulmonologist at the University of Michigan who is leading a clinical study of an investigational COVID-19 vaccine candidate. She helps answer common questions people may have about the process, from what people over 60 need to know to how participants are being kept safe during the pandemic.
